PIP5K1A and neoplasm: Previous studies have shown PIP5K1α as an emerging cancer drug target and a biomarker in prostate cancer, and a small molecule PIP5K1α inhibitor with the ability to suppress tumor growth in a castration-resistant prostate cancer xenograft mouse model [15, 16].